Concourse Financial Group Securities’s Intellia Therapeutics NTLA Stock Holding History

Concourse Financial Group Securities’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5,216	Closed	-$57.4K	–	1382
2024 Q4	$57.4K	Buy	5,216 +2,169	+71%	+$33.9K	﹤0.01%	1156
2024 Q3	$62.6K	Buy	3,047 +521	+21%	+$12K	﹤0.01%	1104
2024 Q2	$56.5K	Buy	2,526 +1,185	+88%	+$28.2K	﹤0.01%	1128
2024 Q1	$36.9K	Buy	1,341 +737	+122%	+$20.5K	﹤0.01%	1307
2023 Q4	$18.4K	Buy	+604	New	+$17.4K	﹤0.01%	1513
2023 Q3	–	Sell	-45	Closed	-$1.75K	–	2384
2023 Q2	$1.83K	Hold	45	–	–	﹤0.01%	2034
2023 Q1	$1.68K	Hold	45	–	–	﹤0.01%	2087
2022 Q4	$1.57K	Hold	45	–	–	﹤0.01%	2081
2022 Q3	$3K	Hold	45	–	–	﹤0.01%	1760
2022 Q2	$2K	Hold	45	–	–	﹤0.01%	2038
2022 Q1	$3K	Hold	45	–	–	﹤0.01%	1969
2021 Q4	$5K	Hold	45	–	–	﹤0.01%	2050
2021 Q3	$6K	Buy	+45	New	+$6.81K	﹤0.01%	2037

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Concourse Financial Group Securities's NTLA Position: Q1 2025 in Review

Concourse Financial Group Securities sold out of Intellia Therapeutics (NTLA) in Q1 2025, closing a stake of 5,216 shares — an estimated $57.4K sold.

Concourse Financial Group Securities first reported a position in NTLA in Q3 2021 and held it in 13 quarters. The position peaked at $62.6K in Q3 2024. 295 funds tracked by Wall St. Rank hold NTLA as of Q1 2025.

Concourse Financial Group Securities reported no remaining Intellia Therapeutics position as of Q1 2025 after selling out during the quarter.
Concourse Financial Group Securities sold 5,216 Intellia Therapeutics shares in Q1 2025, an estimated $57.4K.
Concourse Financial Group Securities first reported a position in Intellia Therapeutics in Q3 2021 and held it in 13 quarters.
Concourse Financial Group Securities's Intellia Therapeutics position peaked at $62.6K in Q3 2024.
295 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2025.

Based on Concourse Financial Group Securities's 13F filing for Q1 2025.